Literature DB >> 18086272

Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes.

Henry T Lynch1, Edibaldo Silva, Carrie Snyder, Jane F Lynch.   

Abstract

Hereditary breast cancer (HBC) accounts for as much as 10% of the total BC burden. Most of these cases will be found to be due to a BRCA germline mutation. An estimated additional 15-20% of those affected with BC will have one or more first- and/or second-degree relatives with BC. Therefore, when these numbers are combined, familial BC risk accounts for approximately 20-25% of the total BC burden. However, because of the often limited information on family history in the etiologic assessment of BC, this may be an underestimate. Confounding factors include its phenotypic and genotypic heterogeneity, given the association of HBC with a plethora of differing cancer syndromes. Its most common occurrence is its association with ovarian cancer in the so-called hereditary breast-ovarian cancer syndrome due to BRCA1 and BRCA2 mutations. More rarely, it occurs in the Li-Fraumeni syndrome, caused by a p53 germline mutation, in which markedly early-onset BC is found in association with brain tumors, sarcomas, leukemia, lymphoma, malignant melanoma, and adrenal cortical carcinoma. Importantly, the age-adjusted incidence of BC in women in the United States fell sharply, by 6.7%, in 2003, when compared with the rate identified in 2002. We postulate that increasing knowledge about the genetics of BC may have partially contributed to the identification of high-risk patients who thereby may have benefited significantly from early diagnosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18086272     DOI: 10.1111/j.1524-4741.2007.00515.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  25 in total

1.  Retrospective comparison of patient outcomes after in-person and telephone results disclosure counseling for BRCA1/2 genetic testing.

Authors:  Courtney Doughty Rice; Jennifer Gamm Ruschman; Lisa J Martin; Jennifer B Manders; Erin Miller
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

2.  Our genes, our selves: hereditary breast cancer and biological citizenship in Norway.

Authors:  Kari Nyheim Solbrække; Håvard Søiland; Kirsten Lode; Birgitta Haga Gripsrud
Journal:  Med Health Care Philos       Date:  2017-03

3.  Association of a functional polymorphism (Gln261Arg) in 12-lipoxygenase with breast cancer.

Authors:  Vidudala V T S Prasad; Padma Kolli; Divya Moganti
Journal:  Exp Ther Med       Date:  2011-01-20       Impact factor: 2.447

Review 4.  Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.

Authors:  Mary Leung; David Rosen; Scott Fields; Alessandra Cesano; Daniel R Budman
Journal:  Mol Med       Date:  2011-03-11       Impact factor: 6.354

5.  Detection of BRCA1 and BRCA2 Ashkenazi Jewish founder mutations in formalin-fixed paraffin-embedded tissues using conventional PCR and heteroduplex/amplicon size differences.

Authors:  Kathy A Mangold; Vivien Wang; Scott M Weissman; Wendy S Rubinstein; Karen L Kaul
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

Review 6.  Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.

Authors:  Frank S Ong; Kingshuk Das; Jay Wang; Hana Vakil; Jane Z Kuo; Wendell-Lamar B Blackwell; Stephen W Lim; Mark O Goodarzi; Kenneth E Bernstein; Jerome I Rotter; Wayne W Grody
Journal:  Expert Rev Mol Diagn       Date:  2012-07       Impact factor: 5.225

7.  BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling.

Authors:  M Sung; P Giannakakou
Journal:  Oncogene       Date:  2013-03-25       Impact factor: 9.867

Review 8.  Hereditary diffuse gastric cancer: prophylactic surgical oncology implications.

Authors:  Henry T Lynch; Edibaldo Silva; Debrah Wirtzfeld; Pamela Hebbard; Jane Lynch; David G Huntsman
Journal:  Surg Clin North Am       Date:  2008-08       Impact factor: 2.741

9.  Declining second primary ovarian cancer after first primary breast cancer.

Authors:  Sara J Schonfeld; Amy Berrington de Gonzalez; Kala Visvanathan; Ruth M Pfeiffer; William F Anderson
Journal:  J Clin Oncol       Date:  2013-01-02       Impact factor: 44.544

Review 10.  Hereditary breast cancer: new genetic developments, new therapeutic avenues.

Authors:  Philippe M Campeau; William D Foulkes; Marc D Tischkowitz
Journal:  Hum Genet       Date:  2008-06-25       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.